iTeos brings on Sanofi cancer VP as CMO as it wades deeper into the clinic

boardroom
Since its $75 million series B round last summer, iTeos has launched a phase 1 trial of its A2A antagonist and slated its TIGIT antibody to enter the clinic later this year. (Pixabay)

Belgian immunotherapy developer iTeos Therapeutics has snagged Sanofi’s cancer drug development leader, Joanne Lager, M.D., to be its new chief medical officer.

The hire comes after the company raised $75 million last June to bring two of its assets to the clinic—an adenosine A2A antagonist and an anti-TIGIT antibody—as well as help fund an expansion to new offices in Cambridge, Massachusetts.

Since the series B round, iTeos has launched a phase 1/1b trial of its A2A antagonist, known as EOS100850, while its TIGIT antibody is slated to enter the clinic in the second half of this year.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We look forward to benefiting from Joanne’s substantial oncology experience and proven clinical development leadership as we continue to design and develop our next generation immunotherapies to improve the lives of cancer patients worldwide,” iTeos President and CEO Michel Detheux said in a statement.

RELATED: iTeos raises $75M to trial immuno-oncology drugs

Starting April 1, Lager will help oversee both programs as CMO, as well as preclinical programs aimed at the tumor microenvironment.

At Sanofi, Lager served as a vice president and head of global oncology development since 2014, after joining the company as an associate VP in 2009.

She helped lead Big Biotech’s clinical development strategy and operations for early and late-stage assets in both blood and solid tumors, and also served as the co-lead of the Oncology Leadership Team, co-chair of the Therapeutic Area Review Committee and chair of the Oncology Protocol Review Committee. Before that, Lager held multiple roles at GlaxoSmithKline, including clinical head of the Cancer Metabolism Discovery Performance Unit.

Suggested Articles

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Elon Musk pulled back the curtain on his brain interface-developing Neuralink, saying the startup holds the promise of merging people with AI.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.